249 related articles for article (PubMed ID: 31454063)
1. Dual inhibition of cannabinoid CB
Udi S; Hinden L; Ahmad M; Drori A; Iyer MR; Cinar R; Herman-Edelstein M; Tam J
Br J Pharmacol; 2020 Jan; 177(1):110-127. PubMed ID: 31454063
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Cannabinoid Receptor 1 Can Influence the Lipid Metabolism in Mice with Diet-Induced Obesity.
Wei LW; Yuan ZQ; Zhao MD; Gu CW; Han JH; Fu L
Biochemistry (Mosc); 2018 Oct; 83(10):1279-1287. PubMed ID: 30472964
[TBL] [Abstract][Full Text] [Related]
3. Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia.
Santos-Molina L; Herrerias A; Zawatsky CN; Gunduz-Cinar O; Cinar R; Iyer MR; Wood CM; Lin Y; Gao B; Kunos G; Godlewski G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443679
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of inducible nitric oxide synthase inhibition on kidney function and structure in high-fat diet-induced kidney disease.
Martin B; Caron N; Jadot I; Colombaro V; Federici G; Depommier C; Declèves AÉ
Exp Physiol; 2018 Jan; 103(1):125-140. PubMed ID: 28944982
[TBL] [Abstract][Full Text] [Related]
5. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia.
Lin CY; Hsu YJ; Hsu SC; Chen Y; Lee HS; Lin SH; Huang SM; Tsai CS; Shih CC
J Mol Cell Cardiol; 2015 Aug; 85():249-61. PubMed ID: 26093151
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.
Dao M; François H
Front Endocrinol (Lausanne); 2021; 12():720734. PubMed ID: 34305821
[TBL] [Abstract][Full Text] [Related]
7. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
[TBL] [Abstract][Full Text] [Related]
8. CB
Cinar R; Park JK; Zawatsky CN; Coffey NJ; Bodine SP; Abdalla J; Yokoyama T; Jourdan T; Jay L; Zuo MXG; O'Brien KJ; Huang J; Mackie K; Alimardanov A; Iyer MR; Gahl WA; Kunos G; Gochuico BR; Malicdan MCV
Clin Transl Med; 2021 Jul; 11(7):e471. PubMed ID: 34323400
[TBL] [Abstract][Full Text] [Related]
9. Increased Contextual Fear Conditioning in iNOS Knockout Mice: Additional Evidence for the Involvement of Nitric Oxide in Stress-Related Disorders and Contribution of the Endocannabinoid System.
Lisboa SF; Gomes FV; Silva AL; Uliana DL; Camargo LH; Guimarães FS; Cunha FQ; Joca SR; Resstel LB
Int J Neuropsychopharmacol; 2015 Jan; 18(8):. PubMed ID: 25618404
[TBL] [Abstract][Full Text] [Related]
10. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.
Cinar R; Godlewski G; Liu J; Tam J; Jourdan T; Mukhopadhyay B; Harvey-White J; Kunos G
Hepatology; 2014 Jan; 59(1):143-53. PubMed ID: 23832510
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.
Tam J
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):267-76. PubMed ID: 26280171
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms.
Roger C; Buch C; Muller T; Leemput J; Demizieux L; Passilly-Degrace P; Cinar R; Iyer MR; Kunos G; Vergès B; Degrace P; Jourdan T
Diabetes; 2020 Oct; 69(10):2120-2132. PubMed ID: 32680936
[TBL] [Abstract][Full Text] [Related]
13. Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity.
Mehrpouya-Bahrami P; Chitrala KN; Ganewatta MS; Tang C; Murphy EA; Enos RT; Velazquez KT; McCellan J; Nagarkatti M; Nagarkatti P
Sci Rep; 2017 Nov; 7(1):15645. PubMed ID: 29142285
[TBL] [Abstract][Full Text] [Related]
14. Peripheral Hybrid CB
Zawatsky CN; Park JK; Abdalla J; Kunos G; Iyer MR; Cinar R
Front Endocrinol (Lausanne); 2021; 12():744857. PubMed ID: 34650521
[TBL] [Abstract][Full Text] [Related]
15. Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling.
Tam J; Szanda G; Drori A; Liu Z; Cinar R; Kashiwaya Y; Reitman ML; Kunos G
Mol Metab; 2017 Oct; 6(10):1113-1125. PubMed ID: 29031713
[TBL] [Abstract][Full Text] [Related]
16. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
Ravinet Trillou C; Delgorge C; Menet C; Arnone M; Soubrié P
Int J Obes Relat Metab Disord; 2004 Apr; 28(4):640-8. PubMed ID: 14770190
[TBL] [Abstract][Full Text] [Related]
17. Monoacylglycerol lipase deficiency affects diet-induced obesity, fat absorption, and feeding behavior in CB
Yoshida K; Kita Y; Tokuoka SM; Hamano F; Yamazaki M; Sakimura K; Kano M; Shimizu T
FASEB J; 2019 Feb; 33(2):2484-2497. PubMed ID: 30265576
[TBL] [Abstract][Full Text] [Related]
18. NESS06SM reduces body weight with an improved profile relative to SR141716A.
Mastinu A; Pira M; Pinna GA; Pisu C; Casu MA; Reali R; Marcello S; Murineddu G; Lazzari P
Pharmacol Res; 2013 Aug; 74():94-108. PubMed ID: 23756200
[TBL] [Abstract][Full Text] [Related]
19. [Role of cannabinoid receptors in renal diseases].
François H; Durrbach A; Beaudreuil S; Charpentier B; Lecru L
Nephrol Ther; 2016 Apr; 12 Suppl 1():S115-22. PubMed ID: 26968477
[TBL] [Abstract][Full Text] [Related]
20. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
